Pan-Cancer Profiling and Digital Pathology Analysis Reveal Negative Prognostic Biomarker ZPR1 Associated with Immune Infiltration and Treatment Response in Hepatocellular Carcinoma
Lian He,Yusai Xie,Yusong Qiu,Yong Zhang
DOI: https://doi.org/10.2147/JHC.S415224
2023-08-10
Journal of Hepatocellular Carcinoma
Abstract:Lian He, 1 Yusai Xie, 2 Yusong Qiu, 1 Yong Zhang 1 1 Department of Pathology, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, Liaoning, 110042, People's Republic of China; 2 Laboratory of Basic Medicine, General Hospital of Northern Theatre Command, Shenyang, Liaoning, 110016, People's Republic of China Correspondence: Yusai Xie, Laboratory of Basic Medicine, General Hospital of Northern Theatre Command, Shenyang, Liaoning, 110016, People's Republic of China, Email Yong Zhang, Department of Pathology, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, Liaoning, 110042, People's Republic of China, Email Purpose: ZPR1 is a zinc finger-containing protein that plays a crucial role in neurodegenerative diseases, lipid metabolism disorders, and non-alcoholic fatty liver disease. However, the expression pattern, prognostic value, and treatment response of ZPR1 in pan-cancer and hepatocellular carcinoma (HCC) remain unclear. Patients and Methods: Pan-cancer expression profiles and relevant clinical data were acquired from UCSC Xena platform. Pan-cancer expression, epigenetic profile, and clinical correlation analysis for ZPR1 were performed. We next explored the prognostic significance and potential biological functions of ZPR1 in HCC. Furthermore, the relationship between ZPR1 and immune infiltration and treatment response was investigated. Finally, quantitative immunohistochemistry (IHC) analysis was applied to assess the correlation of ZPR1 expression and immune microenvironment in HCC tissues using Qupath software. Results: ZPR1 was differentially expressed in most tumor types and significantly up-regulated in HCC. ZPR1 showed hypo-methylated status in most tumors. Pan-cancer correlation analysis indicated that ZPR1 was closely associated with clinicopathological factors and TMB, MSI, and stemness index in HCC. High ZPR1 expression could be an independent risk factor for adverse prognosis in HCC. ZPR1 correlated with immune cell infiltration and therapeutic response. Finally, IHC results suggested that ZPR1 correlated with CD4, CD56, CD68, and PD-L1 expression and is a promising pathological diagnostic marker in HCC. Conclusion: Immune infiltrate-associated ZPR1 could be considered a novel negative prognostic biomarker for therapeutic response in HCC. Keywords: hepatocellular carcinoma, ZPR1, prognosis, digital pathology, pan-cancer Malignant tumor is the second leading cause of death in the world and poses a severe threat to the life and health of all humankind. By 2020, hepatocellular carcinoma (HCC) was the sixth most frequent cancer and the third leading cause of cancer death globally. 1 The 5-year relative survival rate of HCC in the United States is 20%. 2 With the rapid development of precision tumor therapy, it is crucial to develop more sensitive and effective biomarkers to guide the selection of optimal clinical treatment plans effectively. Pan-cancer research combined with multiple omics analysis in specific tumors has been used to identify tumor markers and signaling pathways and help us understand the molecular mechanism of biomarkers in cancer development. ZPR1 zinc finger (ZPR1), also known as ZNF259, is ubiquitously expressed and evolutionarily conserved in mammalian cells. ZPR1 was first found to bind to the tyrosine kinase domain of cytoplasmic epidermal growth factor receptor (EGFR) through the zinc finger domain. 3 ZPR1 has been shown to interbinds with eukaryotic translation elongation factor 1A (eEF1A) to form the ZPR1-eEF1A complex, which is essential for cell replication, cell cycle progression, and survival. 4–6 Increasing evidence has demonstrated that ZPR1 is associated with spinal muscular atrophy (SMA), 7–15 type 2 diabetes, 16 non-alcoholic fatty liver disease (NAFLD), 17 metabolic syndrome, 18 hypertriglyceridemia, 17–23 and growth restriction. 24 In tumors, ZPR1 serves a specific role in carcinogenesis and development. Previous research has reported that ZPR1 is upregulated and promotes the malignant progression of breast cancer. 25 In contrast, Shan et al found that ZPR1 was downregulated and inhibited the proliferation and invasion of lung cancer. 26 To date, the expression level, prognostic value, and potential molecular functions of ZPR1 in pan-cancer and HCC are not clear. Based on the integrated data analyzed from TCGA, GTEx, GENT2, UALCAN, and Kaplan–Meier databases, as well as the experiment validated by IHC assay, our research applied the comprehensive bioinformatics methods to explore the ZPR1 exp -Abstract Truncated-
oncology